Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: A methodological comparison

Summary Mature circulating endothelial cells (CECs) are novel cellular markers of endothelial damage/dysfunction. The two main techniques of CEC enumeration are flow cytometry (FC) and immunomagnetic bead (IB) isolation. Both quantify CECs accurately, but a direct comparison of both methods has not been reported. We sought to assess the agreement between the two methods in two patient populations, and a group of healthy subjects, with emphasis given to methodological issues. We included 34 patients with acute coronary syndrome (ACS), 60 patients with primary breast cancer (PBC) and 30 healthy controls (HC). We quantified CECs using the IB method [CD146 and FITCUlex europaeus lectin-1] and FC [CD45, CD34 and CD146]. Bland-Altman plots suggested reasonable agreement (<5% of events >2 standard deviations from the mean) between FC and the IB methods for CEC quantification in whole blood in the two disease groups (ACS and PBC), but not among the HCs. There were no statistically significant differences in CEC levels by the two methods amongst all three patient groups. There is reasonable agreement between the FC and the IB methods for mature CEC quantification in whole blood, especially amongst disease groups. The agreement between the two methods appears to weaken in healthy controls, and at lower and higher absolute CEC counts.

[1]  A. Blann,et al.  Circulating endothelial cells and endothelial progenitor cells: two sides of the same coin, or two different coins? , 2006, Atherosclerosis.

[2]  E. Voest,et al.  Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Jain,et al.  Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Doyle,et al.  Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. , 2006, Cancer research.

[5]  E. Mohler,et al.  Flow cytometric measurement of circulating endothelial cells: The effect of age and peripheral arterial disease on baseline levels of mature and progenitor populations , 2006, Cytometry. Part B, Clinical cytometry.

[6]  D. Stupack,et al.  A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. , 2006, The Journal of clinical investigation.

[7]  F Dignat-George,et al.  Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry , 2006, Cytometry. Part B, Clinical cytometry.

[8]  M. Haubitz,et al.  Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol , 2006, Journal of thrombosis and haemostasis : JTH.

[9]  G. Lip,et al.  Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. , 2006, Neoplasia.

[10]  B. Thürlimann,et al.  Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer , 2006, British Journal of Cancer.

[11]  C. Gentile,et al.  Presence of endothelial progenitor cells, distinct from mature endothelial cells, within human CD146+ blood cells , 2005, Thrombosis and Haemostasis.

[12]  Ricky T. Tong,et al.  Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. P. McCoy,et al.  CD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral blood. , 2005, Blood.

[14]  M. Haubitz,et al.  Circulating endothelial cells in relapse and limited granulomatous disease due to ANCA associated vasculitis , 2005, Annals of the rheumatic diseases.

[15]  G. Nickenig,et al.  Circulating endothelial progenitor cells and cardiovascular outcomes. , 2005, The New England journal of medicine.

[16]  C. Ponticelli,et al.  Increased levels of circulating endothelial cells in chronic periaortitis as a marker of active disease. , 2005, Kidney international.

[17]  Hong Zhang,et al.  Circulating endothelial progenitor cells in multiple myeloma: implications and significance. , 2005, Blood.

[18]  G. Lip,et al.  Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. , 2005, Blood.

[19]  Françoise Dignat-George,et al.  Circulating endothelial cells , 2005, Thrombosis and Haemostasis.

[20]  E. Voest,et al.  Circulating endothelial cells in cancer patients do not express tissue factor. , 2004, Cancer letters.

[21]  M. Haubitz,et al.  An improved assay for enumeration of circulating endothelial cells , 2004, Annals of Hematology.

[22]  R. Brook,et al.  Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. , 2004, Blood.

[23]  F. Ingegnoli,et al.  Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. , 2004, Arthritis and rheumatism.

[24]  G. Lip,et al.  Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. , 2004, European heart journal.

[25]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[26]  K. Nakatani,et al.  Circulating Endothelial Cells in Kawasaki Disease , 2003, Clinical and experimental immunology.

[27]  M. Haubitz,et al.  Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis , 2003, The Lancet.

[28]  C. Verfaillie,et al.  Origin of endothelial progenitors in human postnatal bone marrow. , 2002, The Journal of clinical investigation.

[29]  A. Goldhirsch,et al.  Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.

[30]  B. Chabrol,et al.  Circulating Endothelial Cells in Behçet’ Disease with Cerebral Thrombophlebitis , 2000, Thrombosis and Haemostasis.

[31]  Robert P. Hebbel,et al.  Sickle Cell Anemia as a Possible State of Enhanced Anti-Apoptotic Tone: Survival Effect of Vascular Endothelial Growth Factor on Circulating and Unanchored Endothelial Cells , 1999 .

[32]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[33]  D. Raoult,et al.  Demonstration of Rickettsia conorii-induced endothelial injury in vivo by measuring circulating endothelial cells, thrombomodulin, and von Willebrand factor in patients with Mediterranean spotted fever [see comments] , 1993 .

[34]  J. Sampol,et al.  Detection of Circulating Endothelial Cells in Thrombotic Thrombocytopenic Purpura , 1993, Thrombosis and Haemostasis.

[35]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[36]  G. Lip,et al.  Circulating endothelial cells: markers of vascular dysfunction. , 2005, Clinical laboratory.

[37]  E. Voest,et al.  Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  A. Blann,et al.  HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Direct Evidence of Endothelial Injury in Acute Myocardial Infarction and Unstable Angina by Demonstration of Circulating Endothelial Cells , 1999 .

[39]  R. Hebbel,et al.  Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. , 1999, Blood.